<p class="Abstract">This randomized controlled clinical trial was conducted to assess the efficacy and safety of intralesional triamcinolone acetonide in the treatment of chronic hand eczema comparing with topical clobetasol propionate. A total 60 patients of chronic hand eczema were recruited in the study. Thirty patients (Group A) were treated with intralesional triamcinolone acetonide and the rest 30 (Group B) with topical clobetasol propionate. Severity and improvement were assessed using Hand Eczema Severity Index (HECSI) score. The patients of both groups were followed up at 4^th week and 12^th week. In Group A, median HECSI score at baseline, 4^th week and 12^th week were 3, 20 and 20 respectively; whereas these scores were 54, 10 and 8 in Group B. In both groups, HECSI score was decreased gradually but the rate was higher in Group B than Group A (p&lt;0.05). Thinning of skin, an adverse effect, was seen in patients of both the intralesional triamcinolone acetonide (10%) and topical clobetasol propionate (16.7%) groups (p&gt;0.05). The result of this study demonstrates that intralesional triamcinolone acetonide is effective and safe in treating chronic hand eczema but less effective than the topical clobetasol.</p>

<p>Cutaneous warts are common skin conditions caused by different specific strains of the human papilloma virus (HPV), mostly affect children as localized lesion on the hands and feet. They are slowly progressing and disseminated lesions are found in immuno-compromised situations. Usually majority of warts disappear by few months to two years. This is a case of extensive, giant, rapidly progressing and resistant warts in an immuno-competent adult male.</p><p> </p>

<p>The study was conducted to evaluate the behavioral factors associated with the development of skin cancer in arsenicosis patients. Arsenicosis patients without skin cancer were taken as control. In the sun-exposed area of the body, 57.2% of skin carcinoma was Bowen’s disease. In the covered area of the body, 56.0% was Bowen’s disease, 36% was squamous cell carcinoma and 8% was basal cell carcinoma. Again, 53.1% of case and 59.4% of control never used fertilizer and pesticide. The majorities were non-smoker (case 53.1%, control 59.3%). Mean cumulative sun exposure was more in the case group (5853.9 ± 2219.7 hours) than in the control group (2219 ± 392.4 hours) and the rate of sun exposure was also higher in the case group. In conclusion, sun exposure was significantly higher in carcinoma patients and since most of the lesions were in the covered areas of the body, it can be said that these carcinomas were due to arsenicosis and not due to sun exposure and smoking status, use of fertilizer and pesticides were not associated with the development of skin carcinoma.</p>

<p><strong>Background:</strong> Acne vulgaris is a chronic inflammatory disease of the pilosebaceous follicles that is seen primarily in adolescents.</p><p><strong>Objective:</strong> To compare the efficacy of 0.1 % tazarotene cream and 0.05% tretinoin cream in the treatment of mild to moderate acne vulgaris.</p><p><strong>Methods:</strong> A randomized controlled clinical trial was done in the department of Dermatol­ogy and Venereology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh.</p><p><strong>Results:</strong> At base line mean number of comedones in group A and group B was 12.77 ± 4.01 and 11.80 ± 3.93 respectively (p=0.350) and at final follow up 4.17 ± 4.02 and 3.47 ± 4.00(p=0.501). At base line mean number ofpapules in group A and group B was 17.30 ± 10.29 and 18.57 ± 13.88 respectively (p=0.690) and at final follow up 7.63 ± 8.08 and 7.73 ± 9.98 (p=0.966). At base line mean number of pustules in group A and group B was 0.50 ± 1.33 and 0.53 ± 1.28 respectively (p=0. 922) and at final follow up 0.07 ± 0.37 and 0.00 (p=0.326). At baseline mean of total acne score was 30.57 ± 13.62 and 30.90 ± 17.17 in group A and B(p=0.934) and at final follow up it was 11.87 ± 12.04 and 11.20 ± 13.85 respectively in group A and B(p=0.846). At 1st follow up 3.3% of both group got excellent response, at 2nd follow up 13.3% of group A and 30.0% of group B got excellent response, and at final follow up 56.7% of group A and 63.3% of group B achieved excel­lent response. About 73.33% oftretinoin treated patient and 60% oftazarotene treated did not experience any side effects.</p><p><strong>Conclusion:</strong> It can be concluded that 0.1 % tazarotene cream and 0.05% tretinoin cream is individually effective and tolerability of 0.1 % tazarotene is comparable to 0.05% tretinoin in the treatment of mild to moderate acne vulgaris.</p>